IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	pplication of: Tetsuo Okada et al.) Confirmation No.: 6009
Application No.: 10/576,774) Group Art Unit: 1624
Filed: March 16, 2007) Examiner: Deepak R Rao
FOR:	Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-Yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic)))))
	Acid and Crystalline Intermediates Thereof) Date: October 16, 2008

INFORMATION DISCLOSURE STATEMENT

<u>UNDER 37 C.F.R. § 1.97(b)</u>

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request that the Examiner consider this Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. patents and publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

Attorney Docket No.: 056291-5278 Application No.: 10/576,774

Page 2

including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: October 16, 2008

Morgan Lewis & Bockius LLP

Customer No. **09629** 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Gregory T. Lowen

Registration No. 46,882 Tel. No.: (202) 739-5915 Fax No.: (202) 739-3001